Graphique du cours de l'action CELC
CELC Gagner
Celcuity Inc
$141.69
-2.26%
$-3.28
À la fermeture : May 05, 16:00:00 GMT-4
$140
-1.19%
$-1.68
Post-Marché: May 05, 20:00:00 GMT-4
Retour
Celcuity Inc (CELC) Gagner
Statistiques clés
Clôture préc.
$144.98
Prix d'ouverture
$146.4
Plage de la journée
$139.8 - $147.33
Plage de 52 semaines
$8.53 - $140
Volume
1.3M
Volume moyen
756.6K
Rendement en dividend
--
BPA (TTM)
-3.78
Capitalisation boursière
$6.7B
Qu’est-ce que CELC ?
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Fonctionnalités
© 2026 Edgen fonctionné par